<DOC>
	<DOCNO>NCT00397813</DOCNO>
	<brief_summary>This phase II trial study side effect best dose total-body irradiation give together fludarabine phosphate follow donor peripheral stem cell transplant treat patient myelodysplastic syndrome ( MDS ) myeloproliferative disorder ( MPD ) . Giving low dos chemotherapy , fludarabine phosphate , total-body irradiation donor peripheral blood stem cell transplant help stop growth cancer cell . Giving chemotherapy radiation therapy transplant also stop patient 's immune system reject donor 's stem cell . The donated stem cell may replace patient 's immune cell help destroy remain cancer cell ( graft-versus-tumor effect ) . Sometimes transplanted cell donor also make immune response body 's normal cell . Giving cyclosporine mycophenolate mofetil transplant may stop happening .</brief_summary>
	<brief_title>Fludarabine Phosphate Total Body Irradiation Followed Donor Peripheral Stem Cell Transplant Treating Patients With Myelodysplastic Syndromes Myeloproliferative Disorders</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Decrease incidence day-200 hematopoietic cell transplantation ( HCT ) failure &lt; 20 % patient MDS-Refractory anemia ( RA ) - ( ringed sideroblast [ RS ] ) /MPD patient chronic myelomonocytic leukemia ( CMML ) /refractory anemia excess blast ( RAEB ) . SECONDARY OBJECTIVES : I . The rate relapse/progression patient MPD MDS-RA CMML MDS-RAEB . II . The probability progression free survival ( PFS ) patient MPD MDS-RA CMML MDS-RAEB . III . The kinetics donor engraftment . IV . The incidence infection . OUTLINE : This dose-escalation study total body irradiation ( TBI ) . NONMYELOABLATIVE CONDITIONING REGIMEN : Patients receive fludarabine phosphate intravenously ( IV ) day -4 -2 undergo TBI day 0 . PERIPHERAL BLOOD STEM CELL ( PBSC ) TRANSPLANTATION : Patients undergo filgrastim ( G-CSF ) -mobilized PBSC infusion TBI day 0 . IMMUNOSUPPRESSION : Matched Related Donor : Patients receive cyclosporine orally ( PO ) twice daily ( BID ) day -3 56 , follow taper day 180 . Patients also receive mycophenolate mofetil ( MMF ) PO BID begin 4-6 hour transplantation day 0 continue day 27 . Unrelated Donor : Patients receive cyclosporine PO BID day -3 100 , follow taper day 180 . Patients also receive MMF PO three time daily begin 4-6 hour transplantation day 0 continue day 40 , follow taper day 96 . After completion study treatment , patient follow periodically .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Anemia , Refractory</mesh_term>
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Thrombocytosis</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic , Atypical , BCR-ABL Negative</mesh_term>
	<mesh_term>Thrombocythemia , Essential</mesh_term>
	<mesh_term>Anemia , Refractory , Excess Blasts</mesh_term>
	<mesh_term>Hemoglobinuria , Paroxysmal</mesh_term>
	<mesh_term>Hemoglobinuria</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Patients age &gt; = 50 &lt; 75 year ( yr ) CMML , previously untreated MDS MPD Patients age &lt; 50 yrs high risk regimen relate toxicity use standard high dose regimen ; factor consider high risk include preexist condition chronic disease affect kidney , liver , lung , heart previous fail HCT An human leukocyte antigen ( HLA ) identical relate HLAmatched unrelated donor ( Fred Hutchinson Cancer Research Center [ FHCRC ] match allow Grade 1.0 2.1 ) available Recovery effect previous chemotherapy , minimum 21 day initiation last therapy ; hydroxyurea anagrelide may use manage elevate cell count patient time begin therapy protocol Patients &lt; 12 yrs age must discuss case case basis primary investigator ( PI ) protocol prior registration A sign informed consent form minor assent form MDS : MDS classifiable World Health Organization ( WHO ) system RA , RARS , refractory cytopenia multilineage dysplasia ( RCMD ) , RCMD ring sideroblast ( RCMDRS ) RAEB MDS : No previous myelosuppressive therapy ; purpose protocol myelosuppressive chemotherapy define chemotherapy give intent induce complete remission ( e.g. , standard 7+3 , high dose intermittent ARAC [ HIDAC ] , Mylotarg ) MDS : Patients must &lt; 10 % marrow blast ; few 10 % marrow blast must document marrow examination within 3 week initiation condition CMML : Patients CMML1 receive myelosuppressive therapy must &lt; 10 % marrow blast ; few 10 % marrow blast must document marrow examination within 3 week initiation conditioning ; OR patient CMML progress beyond CMML1 receive myelosuppressive chemotherapy must &lt; 5 % marrow blast ; few 5 % marrow blast must document marrow examination within 3 week initiation condition MPD : Patients polycythemia vera persistent thrombotic hemorrhagic complication despite conventional therapy , progress postpolycythemic marrow fibrosis MPD : Patients essential thrombocythemia persistent thrombotic hemorrhagic complication despite conventional therapy , progress myelofibrosis MPD : Chronic idiopathic myelofibrosis peripheral blood cytopenia MPD : Patients must &lt; 10 % marrow blast ; few 10 % marrow blast must document marrow examination within 3 week initiation condition MPD : No previous myelosuppressive therapy ; purpose protocol myelosuppressive chemotherapy define chemotherapy give intent induce complete remission ( e.g. , standard 7+3 , HIDAC , Mylotarg ) Atypical chronic myeloid leukemia ( CML ) : Philadelphia chromosomenegative patient diagnosis atypical CML Atypical CML : Patients must &lt; 10 % marrow blast ; few 10 % marrow blast must document marrow examination within 3 week initiation condition Atypical CML : No previous myelosuppressive therapy ; purpose protocol myelosuppressive chemotherapy define chemotherapy give intent induce complete remission ( e.g. , standard 7+3 , HIDAC , Mylotarg ) Paroxysmal nocturnal hemoglobinuria ( PNH ) : Patients nonaplastic form PNH ( cellular bone marrow ) history lifethreatening complication disease include thrombotic event , severe hemolysis Budd Chiari syndrome eligible ; patient may consider follow approval PCC approval Principal investigator Matched Related Donor : Related patient genotypically phenotypically HLAidentical Matched Related Donor : Donor age &lt; 75 yr unless clear institutional PI Matched Related Donor : Capable give write , informed consent Matched Related Donor : Donor must consent PBSC mobilization GCSF apheresis Unrelated Donor : FHCRC match allow grade 1.0 2.1 : Unrelated donor prospectively : 1 . Matched HLAA , B , C , DRB1 DQB1 high resolution typing ; 2 . Only single allele disparity allow HLAA , B , C define high resolution type Unrelated Donor : Patient donor pair homozygous mismatch allele graft rejection vector consider twoallele mismatch , i.e. , patient A*0101 donor A*0102 , type mismatch allow HLA Matched Related Donor : GCSF mobilize peripheral blood mononuclear cell ( PBMC ) permit hematopoietic stem cell ( HSC ) source protocol HLA Matched Unrelated Donor : Donor must consent PBSC mobilization GCSF apheresis ; bone marrow unrelated donor eligible protocol Organ dysfunction define follow : Symptomatic coronary artery disease cardiac ejection fraction &lt; 35 % ( , unable obtain ejection fraction , shorten fraction &lt; 26 % ) ; shorten fraction &lt; 26 % cardiology consult require principal investigator ( PI ) final approval eligibility ; ejection fraction require age &gt; 50 year history anthracycline exposure history cardiac disease Diffusing capacity lung carbon monoxide ( DLCO ) &lt; 35 % , TLC &lt; 35 % , forced expiratory volume ( FEV ) 1 &lt; 35 % and/or receive supplementary continuous oxygen ; FHCRC PI study must approve enrollment patient pulmonary nodule Liver function abnormality : Patient clinical laboratory evidence liver disease evaluate cause liver disease , clinical severity term liver function , bridge fibrosis , degree portal hypertension ; patient exclude he/she find fulminant liver failure , cirrhosis liver evidence portal hypertension , alcoholic hepatitis , esophageal varix , history bleed esophageal varix , hepatic encephalopathy , uncorrectable hepatic synthetic dysfunction evince prolongation prothrombin time , ascites related portal hypertension , bacterial fungal liver abscess , biliary obstruction , chronic viral hepatitis total serum bilirubin &gt; 3mg/dL , symptomatic biliary disease Bone marrow document blast count &gt; = 10 % &gt; = 5 % CMML patient progress beyond CMML1 receive myelosuppressive chemotherapy Patients active nonhematologic malignancy ( except nonmelanoma skin cancer ) ; exclusion apply patient nonhematologic malignancy require therapy Patients history nonhematologic malignancy ( except nonmelanoma skin cancer ) currently complete remission , less 5 year time complete remission , &gt; 20 % risk disease recurrence Presence &gt; = 5 % circulate leukemic blast ( peripheral blood ) detect standard pathology Active central nervous system ( CNS ) involvement disease Karnofsky performance score &lt; 70 % LanskyPlay Performance score &lt; 70 pediatric patient Life expectancy severely limited disease malignancy Fungal infection radiological progression receipt amphotericin product active triazole &gt; 1 month Active bacterial infection Patients fertile age refuse contraception twelve month period posttransplant Females pregnant breastfeed Human immunodeficiency virus ( HIV ) seropositivity Severe psychological illness major psychosis ( e.g . schizophrenia ) , major bipolar depression , suicidal situational depression Matched Related Donor : Identical twin Matched Related Donor : Any contraindication administration subcutaneous GCSF dose 16mg/kg/d five consecutive day Matched Related Donor : Serious medical psychological illness Matched Related Donor : Pregnant lactating female Matched Related Donor : Prior malignancy within precede five yr , exception nonmelanoma skin cancer Matched Related Donor : HIV seropositivity Unrelated Donor : A positive antidonor cytotoxic crossmatch absolute donor exclusion ; donor exclude preexist immunoreactivity identify would jeopardize donor hematopoietic cell engraftment ; determination base standard practice individual institution ; recommended procedure patient 10 10 HLA allele level ( phenotypic ) match obtain panel reactive antibody ( PRA ) screen class I class II antigens patient HCT ; PRA show &gt; 10 % activity , flow cytometric B T cell cytotoxic cross match obtain ; donor exclude cytotoxic cross match assay positive ; patient HLA class I allele mismatch , flow cytometric B T cell cytotoxic cross match obtain regardless PRA result Unrelated Donor : Marrow donor Unrelated Donor : Donors HIVpositive and/or medical condition would result increase risk donor GCSF mobilization GPBMC collection Unrelated Donor : Serious medical psychological illness Unrelated Donor : Pregnant lactating female Unrelated Donor : Prior malignancy within precede five yr , exception nonmelanoma skin cancer Unrelated Donor : HIV seropositivity</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>